EUVIMEDObjevte EUVIMED
CrossrefInformační karta

Efficacy and safety of en bloc resection versus transurethral resection for ureteral orifice-invasive bladder tumors

Shaoan Chen, Yu Zhang, Bangmin Han, Yuyang Zhao

Bladder · 2026

DOI: 10.14440/bladder.0150 ↗
AbstraktBibliografické údaje

Abstrakt

Background: Surgical treatment for ureteral orifice-invasive bladder tumors is tricky and remains controversial. Objective: This study compared the efficacy and safety of thulium laser en bloc resection of bladder tumor (ERBT) and transurethral resection of bladder tumor (TURBT) for ureteral orifice-invasive tumors. Methods: Clinical data of patients with non-muscle invasive bladder tumors close to or invading the ureteral orifice from March 2016 to October 2023 were retrospectively analyzed. Pre-operative imaging confirmed no ureteral dilation or hydronephrosis. Bladder instillation chemotherapy was administered based on the pathological findings. Follow-up with cystoscopy and imaging was conducted every 3 months for 1–2 year(s), and then every 6 months thereafter. Results: Forty-two patients were included (25 ERBT, 17 TURBT). All surgeries were completed without intraoperative complications. Median follow-up lasted for 22 months. Baseline median age (65 vs. 63 years, p=0.27), tumor number (all solitary), and size (2.85 ± 1.06 cm vs. 3.14 ± 0.82 cm, p=0.37) were comparable between the TURBT and ERBT groups. Mean operative time was shorter with ERBT (16.08 ± 3.26 min) than with TURBT (30.00 ± 3.53 min; p=0.01). Post-operative hematuria occurred in two TURBT cases and none in ERBT (p=0.006). Detrusor muscle sampling was missed in seven TURBT cases and none with ERBT (p=0.003). Hospitalization was shorter for ERBT (3.12 ± 0.73 days) than with TURBT (4.53 ± 0.80 days; p=0.04). No short-term ureteral stenosis or hydronephrosis developed in either group. Conclusion: ERBT safely resects ureteral orifice-invasive tumors, avoids double-J stenting, and protects the ureteral orifice, rendering it preferable to TURBT in this setting.

Znalosti, které odpovídají vaší práci.

Od bezplatného začátku přes osobní rešerše literatury až po kompletní Research Suite.

Zobrazit tarify →

Jsou zahrnuty všechny plné texty vydavatelů?

Ne. Bibliografické záznamy, abstrakty a plné texty jsou různé typy obsahu. To, zda je plný text dostupný, závisí na zdroji, Open Access a vašich stávajících licencích. Tarif EUVIMED nenahrazuje dodatečná vydavatelská práva.

Zobrazit tarify →